title: [Daunomycin-human albumin microspheres (dau-ha-ms)--preparation, characterization and use in experimental cancer therapy].
abstract: For the purpose of enhancing the therapeutic index and reducing the toxic effect of chemotherapeutic drugs, Dau-HA-Ms was prepared, mostly as monodispersed microspheres with a mean diameter of 52 +/- 16 microns, ranging from 29 to 194 microns, being suitable for the use of transarterial embolization (TAE) therapy. Dau released effectively in physiological saline solution from microspheres without burst release. The spectrophotometric characteristics and cytotoxic effect in vitro of the released Dau remained unchanged, retaining the original physicochemical and biological properties. It was demonstrated that 30% of mice bearing S-180 sarcoma ascites treated with intraperitoneal injection of Dau-HA-MS survived longer than 6 months, while all tumor bearing control mice and Dau treated tumor bearing mice died within 21 and 14 days, respectively. The results show that Dau-HA-MS is therapeutically more effective and less toxic than Dau, Dau-HA-MS can possibly be used in TAE therapy for human liver cancer.
authors.affiliation: Institute of Radiation Medicine, Academy of Military Medical Sciences, Beijing.
authors.forename: R Z
authors.initials: RZ
authors.lastname: Wang
authors.forename: W Q
authors.initials: WQ
authors.lastname: Zhong
authors.forename: S R
authors.initials: SR
authors.lastname: Guan
mesh_terms: D000818:Animals; D016461:Chemoembolization, Therapeutic; D003630:Daunorubicin / Q000008:administration & dosage*; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008863:Microspheres; D009368:Neoplasm Transplantation; D051381:Rats; D012510:Sarcoma 180 / Q000628:therapy*; D012709:Serum Albumin
chemical_list: D012709:Serum Albumin; D003630:Daunorubicin